We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
Read MoreHide Full Article
Elevance Health, Inc.'s (ELV - Free Report) life and disability business is set to be acquired by StanCorp Financial, a private benefits provider company. This transaction will combine the life and disability businesses of ELV and StanCorp, both having longstanding expertise in employee benefits and a common customer focus. The companies will also enter a product distribution partnership.
This partnership will bring a trusted life and disability partner for Elevance’s customers.ELV’s mission is to improve the health of humanity, and it believes in working together to achieve it. The company strives for opportunities to maximize the power of partnerships to deliver on this mission. As ELV sells its life and disability business to StanCorp, its customers benefit from StanCorp’s expertise in group benefits business and a strong geographic presence.
ELV’s government business contributed 62.2% to its total revenues in 2022. With the sale of the life and disability business, ELV’s resources can be focused on driving growth from its more profitable operations. This will help ELV align its investments to optimize the core business.
Moreover, the company will experience lower expenses as it will save costs to acquire new customers for its life and disability business.This will further boost its bottom line in the future. The cash generated by this transaction will be available for ELV to invest in growth opportunities for the future development of its business.
Elevance Health believes StanCorp will continue to offer its customers best-in-class benefits and services after closing the deal.The financials details of this transaction are yet to be disclosed.
Price Performance
Shares of Elevance Health have 1% in the past 6 months compared with the industry’s decline of 0.2%.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Elevance Health currently carries a Zacks Rank #2 (Buy).
The bottom line of ICON Public outpaced estimates in all the last four quarters, the average surprise being 2.3%.The Zacks Consensus Estimate for ICLR’s 2023 earnings suggests an improvement of 7.9%, while the same for revenues indicates growth of 4.9% from the corresponding year-ago reported figures. The consensus mark for ICLR’s 2023 earnings has moved 1.1% north in the past 60 days.
GeneDx’ bottom line outpaced estimates in two of the trailing four quarters while it missed the other two. The average of earnings surprises is 3.5%.
The Zacks Consensus Estimate for WGS’s 2024 sales indicates a 23.8% rise from the prior-year estimated figures.
The bottom line of MDxHealth outpaced estimates in two of the trailing four quarters, while it missed in the other two, the average surprise being 27%.
The Zacks Consensus Estimate for MDXH’s 2023 revenues indicates growth of 77.5% from the corresponding year-ago reported figures.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elevance (ELV) to Divest Life & Disability Business to StanCorp
Elevance Health, Inc.'s (ELV - Free Report) life and disability business is set to be acquired by StanCorp Financial, a private benefits provider company. This transaction will combine the life and disability businesses of ELV and StanCorp, both having longstanding expertise in employee benefits and a common customer focus. The companies will also enter a product distribution partnership.
This partnership will bring a trusted life and disability partner for Elevance’s customers.ELV’s mission is to improve the health of humanity, and it believes in working together to achieve it. The company strives for opportunities to maximize the power of partnerships to deliver on this mission. As ELV sells its life and disability business to StanCorp, its customers benefit from StanCorp’s expertise in group benefits business and a strong geographic presence.
ELV’s government business contributed 62.2% to its total revenues in 2022. With the sale of the life and disability business, ELV’s resources can be focused on driving growth from its more profitable operations. This will help ELV align its investments to optimize the core business.
Moreover, the company will experience lower expenses as it will save costs to acquire new customers for its life and disability business.This will further boost its bottom line in the future. The cash generated by this transaction will be available for ELV to invest in growth opportunities for the future development of its business.
Elevance Health believes StanCorp will continue to offer its customers best-in-class benefits and services after closing the deal.The financials details of this transaction are yet to be disclosed.
Price Performance
Shares of Elevance Health have 1% in the past 6 months compared with the industry’s decline of 0.2%.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Elevance Health currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the Medical Services industry are ICON Public Limited Company (ICLR - Free Report) , GeneDx Holdings Corp. (WGS - Free Report) and MDxHealth SA (MDXH - Free Report) . ICON Public sports a Zacks Rank #1 (Strong Buy), while GeneDx and MDxHealth carry a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The bottom line of ICON Public outpaced estimates in all the last four quarters, the average surprise being 2.3%.The Zacks Consensus Estimate for ICLR’s 2023 earnings suggests an improvement of 7.9%, while the same for revenues indicates growth of 4.9% from the corresponding year-ago reported figures. The consensus mark for ICLR’s 2023 earnings has moved 1.1% north in the past 60 days.
GeneDx’ bottom line outpaced estimates in two of the trailing four quarters while it missed the other two. The average of earnings surprises is 3.5%.
The Zacks Consensus Estimate for WGS’s 2024 sales indicates a 23.8% rise from the prior-year estimated figures.
The bottom line of MDxHealth outpaced estimates in two of the trailing four quarters, while it missed in the other two, the average surprise being 27%.
The Zacks Consensus Estimate for MDXH’s 2023 revenues indicates growth of 77.5% from the corresponding year-ago reported figures.